# Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus

> **NCT02284009** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 67 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **BIOLOGICAL:** Albiglutide weekly injection
- **BIOLOGICAL:** Placebo weekly injection
- **BIOLOGICAL:** Insulin

## Key facts

- **NCT ID:** NCT02284009
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-10
- **Primary completion:** 2017-10-18
- **Final completion:** 2017-10-18
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2020-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02284009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02284009, "Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02284009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*